New cocktail of drugs targets Hard-to-Treat pancreatic cancer
NCT ID NCT07040228
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a combination of three drugs—regorafenib, toripalimab, and albumin-bound paclitaxel—as a third-line treatment for people with advanced pancreatic cancer that has spread or cannot be removed. The study aims to find the safest dose and see if the combo can slow tumor growth. About 23 participants will receive the drugs until their disease worsens or side effects become too severe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- regorafenib, toripalimab, and albumin-bound paclitaxel
- What this could lead to
- If successful, this could offer a new treatment option for people with advanced pancreatic cancer who have run out of standard therapies.
- What could go wrong
- This is an early-phase trial with only 23 participants, so results may not apply broadly. The drug combination may cause serious side effects or fail to control the cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center
RECRUITINGShenzhen, Guangdong, 518000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI trained on thousands of pancreatic cancer cases could revolutionize diagnosis
- New Antibody-Drug combo takes on Hard-to-Treat pancreatic cancer
- New drug targets Hard-to-Treat pancreatic cancer by hitting a common mutation
- Experimental combo targets Hard-to-Treat pancreatic cancer
- Engineered immune cells take aim at a common pancreatic cancer mutation
- Radioactive injection takes on tough pancreatic cancer in early trial